Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Eli Lilly · Phase 3 · Completed · Enrollment 441

NCT06047548

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Tirzepatide 5 milligram (mg)n/rn/rn/rn/r
Tirzepatide Maximum Tolerated Dosen/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Tirzepatide 5 milligram (mg): endpoint not reported
  • Tirzepatide Maximum Tolerated Dose: endpoint not reported
  • Placebo: endpoint not reported